肝动脉化疗栓塞术和生物反应修饰剂联合治疗中晚期原发性肝癌的临床观察

Treatment for Primary Liver Cancer in Intermediate and Advanced Stage with TAE and BRM

对介入性放射肝动脉化疗栓塞和生物反应修饰剂联合治疗中晚期原发性肝癌３５例的临床疗效进行观察。结果显示：其肿瘤缩小率、ＡＦＰ下降水平和生存期均明显优于对照组。其中６个月生存率为８０％，χ２＝４．４８１６。Ｐ＜０．０５，１年生存率为５７．１％，χ２＝４．４８９５，Ｐ＜０．０５。而且术后并发症或副作用少，能改善病人的生活质量。认为两种手段联合治疗中晚期原发性肝癌是一种比较理想的方法。

We studied the curative effects of the treatment for primary liver cancer in intermediate and advanced stage with TAE and BRM in 35 cases. The results showed that tumor shrinkage, decline in AFP, and survival period of treat group were superior to those of control group. The survival rate within six mouths was 80%, χ 2=4.4816, P<0.05; within one year, 57.15%, χ 2=4.4895, P<0.05. There were few complicating diseases and side effects after operation. And life quality of patients could be improved. We believe that it is ideal to treat primary liver cancer in intermediate and advanced stage with TAE and BRM.